BNP (B-type Natriuretic Peptide) is a hormone produced by the heart, specifically the ventricles, in response to changes in pressure that occur when heart failure develops or worsens. BNP levels are elevated in patients with heart failure, making it a useful biomarker in diagnosing and monitoring the condition. The test can help distinguish between cardiac and non-cardiac causes of symptoms like shortness of breath.
Pathlab has reported BNP levels using the Triage Method and using EDTA plasma as the preferred sample type. The current reference interval is 0-100 ng/L.
From 23 December 2024, the current BNP method will be replaced by NT-proBNP. This method is more specific than BNP, as NT-proBNP has a longer half-life and is less influenced by factors like obesity or kidney function.
This will align / harmonise Pathlab with other central and upper North Island laboratories in regard to BNP testing.
A comparison study was done between Pathlab's new and current methods and Health Waikato laboratory’s cobas method. The comparison showed excellent numerical and clinical correlation.
Changes
Please send any feedback to John Woodford.
Pinnacle has developed a rural chest pain assessment method that allows low-risk patients in rural communities to be safely assessed and managed by their general practice, rather than travelling significant distances to hospital - often needlessly.
Read moreTreatment of patients with suspected ACC related DVT with a Wells Score of >= 2 or a positive D-dimer.
View detailsA range of guides to assist when using the iron infusion programme.